Skip to main content

Drug Interactions between lecanemab and Normiflo

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ardeparin lecanemab

Applies to: Normiflo (ardeparin) and lecanemab

MONITOR CLOSELY: Coadministration with drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight heparins, heparin derivatives, hirudin derivatives and analogs, thrombolytics, vitamin K antagonists, factor Xa inhibitors and other anticoagulants may potentiate the risk of bleeding complications associated with the use of the amyloid beta-directed antibody, lecanemab. Lecanemab therapy has been associated with amyloid related imaging abnormalities (ARIA) with hemosiderin deposition (ARIA-H), including microhemorrhage, superficial siderosis, and intracerebral hemorrhage, including fatal events. According to limited clinical trial data, concomitant use of lecanemab with aspirin, other antiplatelets (e.g., clopidogrel), or anticoagulants (e.g., dabigatran or warfarin) did not lead to an increased risk of ARIA-H compared to placebo; however, the majority of patients who received lecanemab were exposed to aspirin only so no definitive conclusions are possible. In addition, patients with known risk factors for intracerebral hemorrhage were excluded from clinical trials.

MANAGEMENT: Due to the risk of intracerebral hemorrhage, caution and close monitoring are recommended with the use of anticoagulants, antiplatelets, antithrombotics, or thrombolytic agents in patients already being treated with lecanemab, particularly those with risk factors for intracerebral hemorrhage.

References

  1. (2023) "Product Information. Leqembi (lecanemab)." Eisai Inc, 1

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer